Drug Discovery World

OCTOBER 20, 2022

Aqemia’s ‘innovation engine’, the Launchpad, has proven successful in several disclosed and undisclosed collaborations worth up to millions of euros with pharmaceutical companies such as Sanofi, Janssen and Servier.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

pharmaphorum

JANUARY 25, 2022

To demonstrate how quickly the digital therapeutics space is developing, it is easiest to state that the first such therapy was approved in 2018 and since that point the annual investment in the space has more than doubled in the intervening years. Developing a digital therapy. This equated to $21.3 This equated to $21.3

Medicine 111

Medicine In-Vivo In-Vitro Development 111

Drug Discovery World

OCTOBER 19, 2022

Ashley Rein , Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. . Drug discovery and development is a time-consuming and costly endeavour.

Drug Delivery 52

Drug Delivery Drugs Drug Delivery Systems Development 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

JUNE 17, 2022

“The broadly neutralizing antibodies we described were more efficient in vitro than many anti–SARS-CoV-2 monoclonals previously approved by the FDA for treatment or prevention. A modified version of the Cv2.1169 antibody was also effective at treating SARS-CoV-2 infection in mice and hamsters.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

Roots Analysis

DECEMBER 12, 2022

The process of drug development and safety testing is extremely expensive and time-consuming. Animal testing is a vital part of drug development process, which is beneficial for researchers in understanding the cause, diagnosis, and treatment of various medical conditions. Brand Positioning Matrix Of Organ-On-Chip Key Players.

Production 40

Production In-Vitro Branding Marketing 40

Drug Discovery World

OCTOBER 4, 2022

The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. . billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. Organoids are developed using pluripotent stem cells (PSCs) or adult stem cells in a 3D culture matrix, and mimic organs in the human body. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

pharmaphorum

JUNE 9, 2022

It occurs when bacterial pathogens adapt over time to develop resistance to traditional antibiotics, resulting in “superbugs” that are near impossible to treat. Success means developing medicines that will have a profound and transformational impact on improving standards of care for people living with devastating illnesses,”.

Bacteria 104

Bacteria Development In-Vitro Drugs 104

The Pharma Data

DECEMBER 14, 2020

15, 2020 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN ), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) Many drugs fail in clinical trials because of their low blood brain barrier permeability. . DALLAS , Dec. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Drug Discovery World

FEBRUARY 22, 2024

Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. This article is sponsored by Collaborative Drug Discovery. Security built in to CDD Vault is critical when working with multiple CROs.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vivo 52

The Pharma Data

MAY 27, 2022

Glofitamab is being investigated in several clinical trials and explored in earlier lines of lymphoma treatment. It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. After a median follow-up of 12.6 months, 39.4% months, not evaluable]). of patients.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

Drug Discovery World

JULY 22, 2022

For example, in randomised clinical trials of patients with non-small cell lung cancer (NSCLC), pembrolizumab has been shown to be effective in slowing down disease progression and improving survival rates 1. demonstrated the ability to model clinical responses to ACT in autologous HIS mice 4. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

APRIL 23, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia. The median OS was 14.7 months (95% CI: 11.9, months (95% CI: 7.4,

Medicine 40

Medicine In-Vitro Antibody Branding 40

The Pharma Data

APRIL 12, 2023

Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. “We

Antibody 40

Antibody In-Vitro Development Trials 40

Drug Discovery World

JULY 22, 2022

But while psychedelic drug research has witnessed a relative roller-coaster ride of effort since the mid-20th century, more recent interest in the use of psychedelics for treating mental health and psychiatric disorders has spurred a raft of clinical trials 1.

Drugs 98

Drugs In-Vitro In-Vivo Clinical Trials 98

Drug Discovery World

FEBRUARY 15, 2023

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

MAY 29, 2024

SpyBiotech and the University of Oxford Biotechnology company SpyBiotech and University of Oxford have entered a research agreement for the development of a vaccine against Epstein-Barr virus (EBV). Studies have found that EBV triggers a range of very serious health conditions including certain cancers and multiple sclerosis.

Drugs 52

Drugs Gene Editing Life Science Genome 52

Drug Discovery World

JANUARY 23, 2023

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Pioneering work in the mid-2000s, led by the Yamanaka group at Kyoto University, further advanced the field of PSCs.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

pharmaphorum

NOVEMBER 2, 2021

In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours. Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. 1) Medtronic 2022 Revenue: Medtronic reported an annual revenue of $31.69

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

OCTOBER 1, 2020

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. Read on to see.

Trials 52

Trials Allergies In-Vitro Antibody 52

Roots Analysis

MAY 21, 2024

In allogeneic cell therapies, the cells are engineered ( to elicit a desired therapeutic response ) and amplified in-vitro. According to the Alliance for Regenerative Medicine, the number of clinical trials being conducted for allogeneic cell-based cancer therapies increased by 30% over the past five years.

In-Vitro 40

In-Vitro Development Engineer Clinical Trials 40

Drug Discovery World

MAY 10, 2023

Drug discovery and development is an arduous process that can cost upwards of $2.6 This stage is more highly regulated and consists of both preclinical testing and clinical trials. Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92